Vesica Health Announces Publication of Study Demonstrating AssureDx Meaningfully Improves Identification of Hematuria Patients at High Risk for Bladder Cancer

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 10/09/2023.
  • Additional Information
    • Alternate Title:
      VESICA-studyPublished
    • Subject Terms:
      California
    • Abstract:
      IRVINE, Calif., Oct. 9, 2023 /PRNewswire/ -- VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced the peer-reviewed publication of a study demonstrating that its noninvasive, urine-based AssureDx™ genomic test delivers a statistically significant improvement in the identification of patients at increased risk for bladder cancer. Notably, in patients with microhematuria AssureDx delivers an impressive 0.97 AUC with a positive test result resulting in a 5-fold increase in the risk of harboring bladder cancer, compared to the current risk assessment metrics alone. [ABSTRACT FROM PUBLISHER]